Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
ALGS drops 12.49% over 7 days amid optimism for HBV and MASH treatments

ALGS drops 12.49% over 7 days amid optimism for HBV and MASH treatments

Bitget-RWA2025/11/17 20:40
By:Bitget-RWA

- Aligos Therapeutics (ALGS) saw a 12.49% 7-day stock decline despite positive HBV/MASH trial data. - Pevifoscorvir showed superior HBV DNA suppression and safety, with Phase II trials ongoing for 2026-2027 data. - ALG-009 demonstrated metabolic benefits for MASH, positioning Aligos as a key player in liver disease innovation. - Recent 23,600-share equity grants to new hires aim to strengthen R&D capabilities and operational growth.

As of November 17, 2025,

(ALGS) experienced a 5.16% decline over the past day, falling to $0.1512. Over the previous week, the token dropped 12.49%, with a 15.05% decrease in the past month and a 54.95% loss over the last year. Although the price has trended downward, recent advancements in the company’s drug development pipeline have brought into the spotlight within the biopharmaceutical industry.

Encouraging Clinical Results for HBV and MASH

ALGS drops 12.49% over 7 days amid optimism for HBV and MASH treatments image 0
Therapeutics presented promising updates from its ongoing clinical studies at the Jefferies London Healthcare Conference on November 17, 2025. The company’s experimental treatment for chronic hepatitis B, Pevifoscorvir, outperformed standard therapies in reducing HBV DNA and lowering antigen levels. The therapy also showed no signs of resistance and maintained a strong safety record. A global Phase II study is in progress, with interim findings anticipated in 2026 and final results expected in 2027.

At the same time, Aligos shared advancements in its programs targeting MASH and obesity. ALG-009, another leading candidate, has demonstrated greater effectiveness and metabolic improvements, showing significant promise for treating metabolic dysfunction-associated steatohepatitis (MASH). These achievements indicate that the company is making substantial progress in addressing critical gaps in liver and viral disease treatments.

Focused R&D and Clinical Progress

Aligos bases its strategy on scientific innovation, building a pipeline aimed at challenging diseases such as HBV and MASH. During the recent conference, company leaders reiterated their dedication to creating top-tier therapies, highlighting their long-term goal of enhancing patient care through advanced medical solutions.

The company’s ongoing clinical work demonstrates its commitment to assembling a strong portfolio that targets persistent and widespread illnesses. With both Pevifoscorvir and ALG-009 actively being tested, Aligos is set to deliver important clinical data soon, which could impact investor confidence and the company’s market stance.

Stock Option Awards for Recent Employees

On November 14, 2025, Aligos revealed it had granted stock options under its 2024 Inducement Plan to new team members. These non-qualified options were provided to help attract and keep skilled professionals, in accordance with Nasdaq Listing Rule 5635(c)(4). The grant covers 23,600 shares, with the exercise price matching the closing price on the grant date. Vesting will occur over four years, with 25% vesting each year and the remainder vesting monthly, contingent on continued employment.

This initiative highlights the company’s commitment to investing in its personnel, supporting its clinical ambitions, and enhancing operational strength. The equity awards are part of Aligos’ broader growth plan and its mission to bring innovative treatments to patients who need them most.

0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!

You may also like

Bitcoin News Today: "As ETFs Experience Rapid Growth, Metaplanet Remains Steadfast in the Battle for Bitcoin Leadership"

- Metaplanet holds 30,823 BTC, aiming for 210,000 by 2027 via preferred shares. - MicroStrategy's market value discounts raise debt concerns despite CEO's confidence. - ETF growth and institutional interest shift Bitcoin's perception as a long-term asset. - Japan's $2T assets drive Metaplanet's Bitcoin-backed fixed-income strategy.

Bitget-RWA2025/11/18 01:46
Bitcoin News Today: "As ETFs Experience Rapid Growth, Metaplanet Remains Steadfast in the Battle for Bitcoin Leadership"

Bitcoin News Today: Bitcoin’s Plunge Below $96K Sparks Concerns Over a Bear Market Resurgence Similar to 2024

- Bitcoin fell below $96,000, erasing 2025 gains and triggering $44M in liquidations as ETF outflows hit $870M. - Market cap dropped 5.4% to $3.36T, with Ethereum and XRP hitting multi-month lows amid weak demand. - Chain metrics show 815,000 BTC sold by long-term holders, while Bull Score Index collapsed to 20 from 80. - Technical indicators warn of further declines below $93,500, testing 2024 bear market lows if support breaks. - MicroStrategy added $835M BTC despite criticism, but fear/greed index hit 1

Bitget-RWA2025/11/18 01:30

Bitcoin News Today: Bitcoin ETFs See $870M Outflow as Long-Term Holder Selling Drives Price Near $80k

- Bitcoin’s price nears $80,000 as fear indices hit 16, signaling panic-driven capitulation. - $870M ETF outflows and 815,000 BTC sold by LTHs accelerate downward pressure since October. - Key technical levels breached: 365-day SMA broken, 50-week SMA at risk, bear market risks rising. - Ethereum faces 200-day EMA resistance; whales accumulate ETH despite $3.66B in ETF outflows. - STHs near 12.79% losses, 6-12M holder cost basis at $94,000 may offer temporary support.

Bitget-RWA2025/11/18 01:30
Bitcoin News Today: Bitcoin ETFs See $870M Outflow as Long-Term Holder Selling Drives Price Near $80k

Bitcoin News Update: Bitcoin ETF Sees $1.5 Billion Withdrawals While Institutional Investors Increase Their Holdings

- BlackRock's IBIT ETF saw $1.5B net outflows over 10 days as investors reassess Bitcoin exposure amid volatility. - Harvard University boosted IBIT holdings to $442.8M, surpassing its combined stake in major tech firms, while diversifying into gold . - Institutional ownership in IBIT rose to 29% QoQ, with UAE entities and sovereign wealth funds among key holders, signaling crypto's growing institutional acceptance. - KuCoin expanded institutional services as ETF outflows highlight market recalibration, wi

Bitget-RWA2025/11/18 01:30